PMA device
Arista AH Absorbable Hemostatic Particles
Davol, Inc. · Agent, Absorbable Hemostatic, Non-Collagen Based (LMG, Class III) · First FDA decision Sep 26, 2006, newest Jul 6, 2021Surgical bleeding and hemostasis
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
10
PMA pathway
Device trials
3
Naming "Arista AH"
MAUDE reports
134
Brand "Arista AH", since 2015
PubMed studies
29
Mentioning "Arista AH"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Arista AH Absorbable Hemostatic Particles
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 10 decisions filed under this name.
- Arista AH Absorbable Hemostatic ParticlesPMA supplement
P050038-S037 · Decided Jul 6, 2021 · 277 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, non-collagen based (LMG) · General & Plastic Surgery
- ARISTA AH ABSORBABLE HEMOSTATPMA supplement
P050038-S030 · Decided Dec 12, 2016 · 178 days after receipt · Normal 180 Day Track
Device type: Agent, absorbable hemostatic, non-collagen based (LMG) · General & Plastic Surgery
- ARISTA AH ABSORBABLE HEMOSTAT AND FLEXTIP APPLICATORSPMA supplement
P050038-S022 · Decided Sep 24, 2014 · 148 days after receipt · Normal 180 Day Track No User Fee
Device type: Agent, absorbable hemostatic, non-collagen based (LMG) · General & Plastic Surgery
3 more FDA decisions with a free account
Older decisions: P050038-S004, P050038-S002, P050038-S001, P050038
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Arista AH", any status and sponsor, newest update first.
- Efficacy of ARISTA-AH for Restoring Hemostasis Following Posterior Long-segment Spinal Fusion.Completed
Polyclinique Bordeaux Nord AquitaineAcademic, hospital or other
NCT05323448 · 91 participants · Start Oct 25, 2022 · Primary completion Mar 9, 2025
Device: Control Group; ARISTA · For: Hemostatics; Hemostasis; Spinal Deformity and 1 more
Sites: Bordeaux, France
- Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic SystemPivotal-lookingCompleted
Artivion Inc.Public (AORT)
NCT02359994 · 324 participants · Start Apr 2015 · Primary completion Jan 11, 2019
Device: PerClot Polysaccharide Hemostatic System; Arista AH · For: Blood Loss, Surgical
Sites: Indianapolis, Indiana
University of California, San FranciscoAcademic, hospital or other
NCT02568085 · 0 participants · Start Mar 2016 · Primary completion Mar 2017
Device: Arista · For: Thyroidectomy; Seroma
Sites: San Francisco, California
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Arista AH", and for the whole product code for context.
This brand
134 reports: 24 malfunction, 109 injury, 1 death
Whole product code LMG
1,626 reports: 410 malfunction, 1,192 injury, 23 death
Newest reports for this brand
- Arista AHInjury
Davol Inc., Sub. C.R. Bard, Inc. -1213643
1213643-2026-01058 · Received Aug 18, 2026 · Event dated Jul 31, 2026
Device type: Agent, Absorbable Hemostatic, Non-Collagen Based (LMG)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: Seroma
- Arista AHInjury
Davol Inc., Sub. C.R. Bard, Inc. -1213643
1213643-2026-01059 · Received Aug 18, 2026 · Event dated Jul 31, 2026
Device type: Agent, Absorbable Hemostatic, Non-Collagen Based (LMG)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: Bruise/Contusion
- Arista AHInjury
Davol Inc., Sub. C.R. Bard, Inc. -1213643
1213643-2026-00960 · Received Jul 28, 2026 · Event dated Jul 9, 2026
Device type: Agent, Absorbable Hemostatic, Non-Collagen Based (LMG)
Device problem as coded: Patient-Device Incompatibility
Patient problem as coded: Rash
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Arista AH"[tiab]. The summary above synthesizes these.
- The use of Arista AH as a local haemostatic agent in distal splenopancreatectomy: report of two cases.
Di Benedetto M, Gramellini M, Bona S, et al. · Drugs Context · 2024
- Review of Evidence Supporting the Aristaࡊ Absorbable Powder Hemostat.
LyBarger KS · Med Devices (Auckl) · 2024Review
- Bronchial Hemorrhage Control Using Arista AH: A Novel Bronchoscopic Approach.
Villena-Vargas J, Voza F, Mick S, et al. · J Bronchology Interv Pulmonol · 2021
- Absorbable Powder Haemostat Use in Minimally Invasive Thoracic Surgery.
Ricciardi S, Patel AJ, Alunni Fegatelli D, et al. · J Clin Med · 2024
- Effect of Microporous Polysaccharide Particles in Patients Undergoing Mastectomy.
Selfridge JM, Sinner HF, Whiting J, et al. · Clin Breast Cancer · 2022Research Support, N.I.H., Extramural
- Hemostatic efficacy of composite polysaccharide powder (starch-chitosan) for emergency bleeding control: An animal model study.
Mardani M, Eftekharian HR, Naseri M, et al. · Surgery · 2022Research Support, Non-U.S. Gov't
- Hemostatic Efficacy and Biocompatibility Evaluation of a Novel Absorbable Porous Starch Hemostat.
Zhu J, Wu Z, Sun W, et al. · Surg Innov · 2022
- Comparison of adhesion prevention capabilities of the modified starch powder-based medical devices 4DryField® PH and Aristaࡊ AH in the Optimized Peritoneal Adhesion Model.
Poehnert D, Neubert L, Klempnauer J, et al. · Int J Med Sci · 2019
- Evaluation of Absorbable Hemostatic Powder for Prevention of Lymphoceles Following Robotic Prostatectomy With Lymphadenectomy.
Gilbert DR, Angell J, Abaza R · Urology · 2016
- Microporous polysaccharide hemosphere absorbable hemostat use in cardiothoracic surgical procedures.
Bruckner BA, Blau LN, Rodriguez L, et al. · J Cardiothorac Surg · 2014Evaluation Study, Research Support, Non-U.S. Gov't
- A Prospective Analysis of the Effects of a Powder-Type Hemostatic Agent on the Short-Term Outcomes after Liver Resection.
Kang M, Cho JY, Han HS, et al. · Medicina (Kaunas) · 2024
- Efficacy of hemostatic matrix and microporous polysaccharide hemospheres.
Lewis KM, Atlee H, Mannone A, et al. · J Surg Res · 2015Evaluation Study
Other devices of this type
Also filed under product code LMG.
- PerClot® Polysaccharide Hemostatic SystemBaxter Healthcare Corporation · PMA 2026
- SURGICEL Endoscopic ApplicatorETHICON, Inc. · PMA 2018
- Surgicel / Surgicel Nu-Knit / Surgicel Fibrillar Absorbable HemostatETHICON, Inc. · PMA 2005
- SURGICELTM POWDER Absorbable Hemostatic PowderETHICON, Inc. · PMA 2026
- Surgicel Powder Absorbable Hemostatic PowderETHICON, Inc. · PMA 2017
- Arista Ah, Arista Ah Flexitip/ Flexitip Xl/ Flexitip Xl-RDavol, Inc. · PMA 2015
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.